Clinical trials: Prostate Cancer Stage
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Prostatic Neoplasm
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
The current study involves a novel and aggressive therapeutic approach for patients' prostate cancer. In addition, the investigators propose to administer hormonal therapy to patients with an especially high risk: those with…
- Trial name
- NCT00956228
- Testing
- radioimmuniguided intenstiy modulated radiotherapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
This phase II trial studies how well abiraterone acetate, prednisone, and apalutamide work in treating patients with hormone-naive prostate cancer that has spread to other places in the body.
- Conditions
- Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03821792
- Testing
- Abiraterone Acetate, Apalutamide, Prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Green tea extract contains substances that may slow the growth of certain cancers and may prevent the development of new cancers.
- Trial name
- NCT00005828
- Testing
- green tea extract
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer, Prostatic Neoplasms
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
To determine: Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer. Group A - subjects who have not previously received chemotherapy Group B - sujects who have received prior chemotherapy…
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate
- Trial name
- IPI-504-04 (NCT00564928)
- Testing
- IPI-504
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Metastatic Cancer, Neoplasm, Prostate
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC.
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Trial name
- NCT05422911
- Testing
- Abiraterone acetate, Apalutamide, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 192 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT03741712
- Testing
- SHR3680, SHR2554
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer Patients Undergoing Radical Prostatectomy
Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer
a single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
- Trial name
- DGPR1008 (NCT07024030)
- Testing
- 0.02mg/kg, 0.04mg/kg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Haitao Niu, MD
Prostate Cancer
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
- Trial name
- NCT00005028
- Testing
- bryostatin 1, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Maryland, Baltimore
Prostatic Neoplasms
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic…
- Trial name
- PSMAfore (NCT04689828)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 72 sites in United States, Austria and 12 more
- Volunteers
- 469 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate
In North America, around a quarter a million men are diagnosed with prostate cancer every year, and about 31,000 patients will die of their disease each year.
- Trial name
- NCT01444820
- Testing
- hypofractionation, conventional
- Where
- 12 sites in Canada
- Volunteers
- 329 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Prostate Cancer
Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to determine the effectiveness of genistein in treating patients who have…
- Trial name
- NCT00005827
- Testing
- genistein
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage I Breast Cancer, Stage II Breast Cancer
Acupuncture Pilot Study for Cancer-related Cognitive Function
This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Colorectal Cancer
- Trial name
- NCT04007770
- Testing
- Acupuncture, 16 week waiting period + optional Acupuncture
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostate Cancer
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Despite improvements in treatment, metastatic prostate cancer remains incurable, especially in the case of pretreated metastatic castration-resistant disease (mCRPC), where treatment options are limited, leading to an unmet need.
- Trial name
- NCT06401980
- Testing
- Darolutamide, Standard of care
- Where
- 13 sites in Switzerland
- Volunteers
- 162 people
- Sponsor
- Swiss Cancer Institute
ATM Gene Mutation, BRCA1 Gene Mutation
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone
- Trial name
- NCT03442556
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Prostate Cancer
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
- Trial name
- NCT01591122
- Testing
- Abiraterone acetate and prednisone
- Where
- 22 sites in China, Malaysia and 2 more
- Volunteers
- 313 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific…
- Trial name
- NCT00001382
- Testing
- PROSTVAC
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate
Enzalutamide in Patients With High-risk Prostate Cancer
The purpose of this study is to see how long it takes for prostate cancer to come back in patients who have had surgery to remove their prostate gland (radical prostatectomy), while being treated with enzalutamide (formerly known…
- Trial name
- NCT01927627
- Testing
- enzalutamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.